Good morning, everyone, and nice to see you again. A sunny day is unfolding here on the Pharmalot corporate campus, where we are brewing our mandatory cup of stimulation. This looks to be a busy day filled with meetings and deadlines. We know you can relate. So grab your own cup of something and dig in to read the news of the world. Remember to stop back as we update this post each morning. Have a good one and do stay in touch...
Vaginal Gel Reduces Premature Births In Some Women (Associated Press)
Astra Heart Drug Faces Tough Hurdle In EU Market (Reuters)
Novartis Gilenya MS Pill To Cost $34K In Germany (Bloomberg News)
Optimer Antibiotic Wins FDA Panel Backing (Xconomy)
Actelion Adds Former Glaxo And Schering Execs To Its Board (Dow Jones)
HPV Might Be Linked To Lung Cancer (Health Day)
Cephalon Board Rejects $7.5B Valent Offer As Too Low (Bloomberg News)
Supreme Court Block Texas From Using Pentobarb For Execution (Associated Press)
FDA Issues Guidance On Cross-Contamination Prevention (InPharma Technologist)
Estrogen Hormone Therapy Risks Fade After Treatment Ends (Reuters)
Japanese Drugmakers In US Face Radiation Challenge (The Star-Ledger)
2 Comments
Interesting that sodium pentobarbital is a drug of choice in countries practicing physician-assisted suicide, but it can't be used for lethal injection .here
The problem with the Japanese drugmakers is that even if they put radiation dosimeters in the shipments to the US, no one has a clue as to what might be considered a "safe" level of radioactivity that might be absorbed. Maybe they could put a few lab rats in the shipments, sacrifice them after product is received, necropsy their tissues, then try to make some correlations with human radiation exposure. They could even do a radation count on the rat droppings to see how much is excreted.